Journal Information
Vol. 40. Num. 4.October - December 2018
Pages 293-392
Download PDF
More article options
Vol. 40. Num. 4.October - December 2018
Pages 293-392
Scientific Comment
DOI: 10.1016/j.htct.2018.05.008
Open Access
A future without human leukocyte antigens?
Simone Cristina Olenscki Gilli
Corresponding author

Correspondence to: Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas, Rua Carlos Chagas, 480, Barão Geraldo, 13083-970 Campinas, SP, Brazil.
Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
Related content
hematol Transfus Cell Ther.2018;40:298-30410.1016/j.htct.2018.03.004
Millena Gomes Ferreira, Fernanda Bernadelli De Vito, Aline Aparecida Ferreira, Carolina Bonet Bub, Fernando Antônio Vinhal dos Santos, Adilson Botelho Filho, Sheila Soares Silva, Helio Moraes-Souza
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Full Text

Platelet transfusion is an essential supportive therapy for patients with hemato-oncological disorders as many of them present with thrombocytopenia and bleeding. Platelet refractoriness, defined as the lack of adequate post-transfusion platelet count increment, remains a challenge in the management of platelet transfusion dependent patients. The majority of refractory cases have nonimmune causes and include infection/sepsis, fever, splenomegaly, use of antibiotics and even storage conditions.1 Immune causes comprise ABO incompatibility, antibodies against class I human leukocyte antigens (HLA) (mostly HLA-A and HLAB), and antibodies against human platelet antigens (HPA). In hematology/oncology patients, platelet refractoriness has been reported in 7–34% of cases.2

The transfusion needs of patients with immune platelet refractoriness triggers a series of processes that include the identification of the immune cause, the search for and notification of compatible donors in a genotyped donor bank, the donation of the actual blood product and finally its release and availability for use. These are lengthy procedures, which are costly and often unsuccessful. On the other hand, we have the refractory patient, bleeding or at imminent risk of bleeding, where urgency and agility are essential. These are two dissonant situations attempting to converge on the same goal. In this regard, despite the few studies that rigorously assess bleeding in patients requiring cross-matched platelet support, the refractory state is associated with increased mortality.3

Thus, the development of technologies that aim to optimize the availability of the blood product as described by Ferreira et al. who report the use of a tool which identifies potential donors even with a limited database of genotyped donors, are extremely welcome in transfusion medicine and are important weapons in the management of these cases.4 Nevertheless, processing constraints remain and are the basis for potentially fatal situations.

Against this background, solutions must be obtained. The ex vivo production of HLA-free transfusion products represents an alternative.

In 1995, Choi et al. described the possibility of generating CD34+ hematopoietic progenitor cell (HPC)-derived platelets in vitro using thrombopoietin (TPO) and a specific cytokine cocktail.5 Since then, many groups have investigated the feasibility of producing platelets from umbilical cord blood, peripheral blood progenitor cells, bone marrow progenitor cells and human embryonic stem cells.6–10

Recently, the feasibility of generating mature functional megakaryocytes from human pluripotent stem cells has been demonstrated.11,12 Human induced pluripotent stem cells (iPSCs) represent an unlimited cell source for the production of blood products. Additionally, iPSC-based blood pharming approaches have been combined with genome editing technology.13 Despite the fact that all of these approaches hold a great potential in the field of transfusion, the probable HLA-incompatibility with the recipient remains a major hurdle to their future application. To circumvent this problem there is an interesting proposal to generate platelets by using transcription activator-like effector nuclease (TALEN)-mediated targeted disruption of the β2 microglobulin gene. Knocking out β2M expression eliminates HLA class I cell-surface expression, which is thought to be a major cause of platelet refractoriness.2 Figueiredo et al. demonstrated a stable reduction of HLA class I surface expression obtained by using a combination of lentiviral gene transfer and RNA interference technology to target the conserved β2m molecule which is an essential part of dimeric HLA class I molecules.9 By this methodology, the authors revealed the capacity of HLA-silenced megakaryocytes, such as platelets, to escape anti-HLA antibody-mediated cytotoxicity.

Altogether, these studies show the feasibility of pharming producing engineered platelets in vitro with advantageous features that promote their maximal therapeutic efficacy. The next challenge in this field is the production of clinically relevant platelet numbers. Indeed, some research groups have already shown the feasibility of producing platelets in bioreactors.14,15 Their use for the large-scale production of universal platelets may open a new horizon in the field of transfusion medicine.

Conflicts of interest

The author declares no conflicts of interest.

S.J. Slichter,K. Davis,H. Enright,H. Braine,T. Gernsheimer,K.J. Kao
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients
E. Hod,J. Schwartz
Platelet transfusion refractoriness
Br J Haematol, 142 (2008), pp. 348-360
J.L. Kerkhoffs,J.C. Eikenboom,L.M. Van De Watering,R.J. Van Wordragen-Vlaswinkel,P.W. Wijermans,A. Brand
The clinical impact of platelet refractoriness: correlation with bleeding and survival
Transfusion, 48 (2008), pp. 1959-1965
M.G. Ferreira,F.B. De Vito,A.A. Ferreira,C.B. Bub,F.A. Dos Santos,A. Botelho Filho
Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusions
Hematol Transfuns Cell Ther, 40 (2018), pp. 298-304
E.S. Choi,J.L. Nichol,M.M. Hokom,A.C. Hornkohl,P. Hunt
Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional
Blood, 85 (1995), pp. 402-413
T. Matsunaga,I. Tanaka,M. Kobune,Y. Kawano,M. Tanaka,K. Kuribayashi
Ex vivo large-scale generation of human platelets from cord blood CD34 + cells
Stem Cells, 24 (2006), pp. 2877-2887
C. De Bruyn,A. Delforge,P. Martiat,D. Bron
Ex vivo expansion of megakaryocyte progenitor cells: cord blood versus mobilized peripheral blood
Stem Cells Dev, 14 (2005), pp. 415-424
F. Norol,N. Vitrat,E. Cramer,J. Guichard,S.A. Burstein,W. Vainchenker
Effects of cytokines on platelet production from blood and marrow CD34+ cells
Blood, 91 (1998), pp. 830-843
C. Figueiredo,L. Goudeva,P.A. Horn,B. Eiz-Vesper,R. Blasczyk,A. Seltsam
Generation of HLA-deficient platelets from hematopoietic progenitor cells
S.J. Lu,F. Li,H. Yin,Q. Feng,E.A. Kimbrel,E. Hahm
Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice
Cell Res, 21 (2011), pp. 530-545
T. Moreau,A.L. Evans,L. Vasquez,M.R. Tijssen,Y. Yan,M.W. Trotter
Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming
Nat Commun, 7 (2016), pp. 1-15
A. Baigger,R. Blasczyk,C. Figueiredo
Towards the manufacture of megakaryocytes and platelets for clinical application
Transfus Med Hemother, 44 (2017), pp. 165-173
Q. Feng,N. Shabrani,J.N. Thon,H. Huo,A. Thiel,K.R. Machlus
Scalable generation of universal platelets from human induced pluripotent stem cells
Stem Cell Rep, 3 (2014), pp. 817-831
J.N. Thon,L. Mazutis,S. Wu,J.L. Sylman,A. Ehrlicher,K.R. Machlus
Platelet bioreactor-on-a-chip
Blood, 124 (2018), pp. 1857-1868
Y. Nakagawa,S. Nakamura,M. Nakajima,H. Endo,T. Dohda,N. Takayama
Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes
Exp Hematol, 41 (2013), pp. 742-748

See paper by Ferreira MG et al. on pages 298–304.

Copyright © 2018. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Hematology, Transfusion and Cell Therapy

Subscribe to our Newsletter

Article options
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.